Men's Health News

RSS

Study shows GreenLight laser therapy effective for BPH treatment

Data presented at the American Urological Association Annual Meeting demonstrate that treatment for Benign Prostatic Hyperplasia with GreenLight XPS laser therapy with MoXy fiber, instead of transurethral resection of the prostate, results in significantly shorter hospitalization, catheterization, and recovery times for patients, while maintaining equivalent safety and efficacy.

4 Jun 2013

SLU assistant professor receives grant to identify policies that improve health of African-American men

An assistant professor at Saint Louis University's College for Public Health and Social Justice has received a $100,000, two-year grant from the Robert Wood Johnson Foundation to determine which behaviors and policies are most likely to improve the health of African-American men.

31 May 2013

FDA issues complete response letter to Endo's NDA for AVEED injection

Endo Pharmaceuticals Inc., a subsidiary of Endo Health Solutions Inc. announced today that the U.S. Food and Drug Administration has issued a complete response letter regarding the New Drug Application for Endo's long-acting testosterone undecanoate injection, AVEED, for men diagnosed with hypogonadism.

31 May 2013

Cancer: The No. 1 health concern among middle-income Americans

Cancer is the No. 1 health concern among our country's middle-income Americans, according to a new study released by Washington National Institute for Wellness Solutions.

29 May 2013

New approach to battle prostate cancer

Dr. Jung-Mo Ahn, associate professor of chemistry at The University of Texas at Dallas, has designed and synthesized a novel small molecule that might become a large weapon in the fight against prostate cancer.

29 May 2013

UT Southwestern researchers develop new class of drugs for prostate cancer

A new study on prostate cancer describes a novel class of drugs developed by UT Southwestern Medical Center researchers that interrupts critical signaling needed for prostate cancer cells to grow.

29 May 2013

African Americans with prostate cancer experience longer treatment delays after diagnosis

Among men with prostate cancer, African Americans experience longer treatment delays after being diagnosed than Caucasians. That is the finding of an analysis published early online in CANCER, a peer-reviewed journal of the American Cancer Society.

28 May 2013

Astellas submits application for marketing approval of enzalutamide for prostate cancer

Astellas Pharma Inc. and Medivation, Inc. today announced that Astellas has submitted an application for marketing approval of enzalutamide (generic name) to the Ministry of Health, Labour and Welfare in Japan for the treatment of prostate cancer.

24 May 2013

Researchers use data to identify different forms of prostate cancers and effective treatment options

Some prostate cancer patients unnecessarily undergo surgery or harsh treatments because science fails to identify the differences between slow-growing and aggressive forms of the disease. Researchers at Case Western Reserve University and Johns Hopkins Medical Institutes are developing technology that allows patients to safely choose to do nothing, opt for relatively mild treatments or take drastic measures.

24 May 2013

Some aggressive forms of prostate cancer have similar genetic origins

Mayo Clinic researchers have used next generation genomic analysis to determine that some of the more aggressive prostate cancer tumors have similar genetic origins, which may help in predicting cancer progression. The findings appear online today in the journal Cancer Research.

24 May 2013

New campaign aims to increase awareness of HIPAA rights, benefits among HIV-positive Black MSM

The U.S. Department of Health and Human Services, Office for Civil Rights is proud to launch the Information Is Powerful Medicine campaign.

24 May 2013

Researchers explore targeted therapies for prostate cancer

Are certain drugs more effective against some types of prostate cancers than others? Researchers know that not all therapies work for all patients – the next question is to figure out how to match the right treatments with the right patients.

24 May 2013

SonaCare Medical highlights need for image-guided technologies to better identify prostate cancer

The need to add tissue preserving therapies to the prostate cancer treatment continuum was highlighted prominently at the 108th Annual Meeting of the American Urological Association, in San Diego.

24 May 2013

FDA gives Priority Review to Celgene's ABRAXANE sNDA for advanced pancreatic cancer

Celgene International Sàrl, a subsidiary of Celgene Corporation today announced that the U.S. Food and Drug Administration has assigned a Priority Review designation to the supplemental New Drug Application for the use of ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine for the first-line treatment of patients with advanced pancreatic cancer.

23 May 2013

UC Irvine chemists create new method to identify clinically usable markers for prostate cancer in urine

Early screening for prostate cancer could become as easy for men as personal pregnancy testing is for women, thanks to UC Irvine research published today in the Journal of the American Chemical Society.

23 May 2013

Research suggests that IMRT may not be more effective in patients who had prostatectomy

Intensity-modulated radiation therapy has become the most commonly used type of radiation in prostate cancer, but research from the University of North Carolina suggests that the therapy may not be more effective than older, less expensive forms of radiation therapy in patients who have had a prostatectomy.

22 May 2013

Findings suggest that a prosaposin-based drug could block metastasis spread

By studying the roles two proteins, thrombospondin-1 and prosaposin, play in discouraging cancer metastasis, a trans-Atlantic research team has identified a five-amino acid fragment of prosaposin that significantly reduces metastatic spread in mouse models of prostate, breast and lung cancer.

22 May 2013

No significant benefit differences between IMRT and CRT therapies after prostatectomy

Use of the newer, more expensive intensity-modulated radiotherapy (IMRT) and use of the older conformal radiotherapy (CRT) after surgical removal of all or part of the prostate gland were associated with similar morbidity and cancer control outcomes, according to a study published Online First by JAMA Internal Medicine, a JAMA Network publication.

21 May 2013

UCLA study: Older men with multiple underlying health problems should avoid prostate cancer treatment

Older prostate cancer patients with other underlying health conditions should think twice before committing to surgery or radiation therapy for their cancer, according to a multicenter study led by researchers in the UCLA Department of Urology.

21 May 2013

Article examines global health policies and burden of disease on men

Men experience a higher burden of disease and lower life expectancy than women, but policies focusing on the health needs of men are notably absent from the strategies of global health organisations, according to a Viewpoint article in this week's Lancet.

18 May 2013

Men's Health News

Study shows GreenLight laser therapy effective for BPH treatment

SLU assistant professor receives grant to identify policies that improve health of African-American men

FDA issues complete response letter to Endo's NDA for AVEED injection

Cancer: The No. 1 health concern among middle-income Americans

New approach to battle prostate cancer

UT Southwestern researchers develop new class of drugs for prostate cancer

African Americans with prostate cancer experience longer treatment delays after diagnosis

Astellas submits application for marketing approval of enzalutamide for prostate cancer

Researchers use data to identify different forms of prostate cancers and effective treatment options

Some aggressive forms of prostate cancer have similar genetic origins

New campaign aims to increase awareness of HIPAA rights, benefits among HIV-positive Black MSM

Researchers explore targeted therapies for prostate cancer

SonaCare Medical highlights need for image-guided technologies to better identify prostate cancer

FDA gives Priority Review to Celgene's ABRAXANE sNDA for advanced pancreatic cancer

UC Irvine chemists create new method to identify clinically usable markers for prostate cancer in urine

Research suggests that IMRT may not be more effective in patients who had prostatectomy

Findings suggest that a prosaposin-based drug could block metastasis spread

No significant benefit differences between IMRT and CRT therapies after prostatectomy

UCLA study: Older men with multiple underlying health problems should avoid prostate cancer treatment

Article examines global health policies and burden of disease on men

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Latest News